Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally.
The last earnings update was 30 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Protalix BioTherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Protalix BioTherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Protalix BioTherapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Protalix BioTherapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Protalix BioTherapeutics's regulatory filings and announcements.
Protalix BioTherapeutics's earnings are expected to grow significantly at over 20% yearly.
Protalix BioTherapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Protalix BioTherapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Protalix BioTherapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Protalix BioTherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Protalix BioTherapeutics's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Protalix BioTherapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Protalix BioTherapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Moshe Manor has been the Chief Executive Officer and President of Protalix BioTherapeutics, Inc. since November 01, 2014. Mr. Manor is the Founder and Owner MACOI. Mr. Manor served as the Chief Executive Officer of Teva Asia & Pacific at Teva Pharmaceutical Industries Limited and served as its President of Teva Asia & Pacific since October 2010, President of Asia Region since August 2010, Group Vice President of Global Branded Products from January 2009 to August 2010, Group Vice President of Global Innovative Resources from 2006 to 2008 and Vice President of Global Products Division from 2002 to January 2006. Mr. Manor brings an extensive and diverse experience acquired during the last 28 years at Teva Pharmaceutical Industries in various positions, both with line and staff responsibility, in the generics and innovative arenas. He has served in a number of senior executive positions at Teva Pharmaceutical Industries Limited from 1984 to 2012. He served as a Vice President of Global Products Division at Teva Pharmaceutical Finance LLC since 2002. Mr. Manor served as Vice President of Strategic Product Planning at Teva Pharmaceutical Finance LLC from 2000 to 2002 and as Vice President Israel Pharmaceutical Sales from 1995 to 2000. He served as the General Manager of Teva-labeled products in Israel from 1993 to 1994 and as the Marketing Director of the Israeli Pharmaceutical Division from 1989 to 1993. He serves as the Chairman of MEway Pharma LTD. He has been a Director of Protalix BioTherapeutics, Inc. since November 01, 2014 and Coronis NeuroSciences Ltd. He served as a Director of Kamedis Ltd. Previously, he served as Director of Teva Israel. Mr. Manor served on the Board of Directors of Coronis Partners. Mr. Manor holds a B.A. in Economics from the Hebrew University in 1982 and his M.B.A. from Tel Aviv University in 1985.
Moshe's compensation has been consistent with company performance over the past year.
Moshe's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Protalix BioTherapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO, President & Director
Founder and Executive VP Research & Development
Senior Vice President of Operations
Senior Vice President of Product Development
Vice President of Human Resources
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Protalix BioTherapeutics board of directors is about average.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.